Imidazopyrimidines as transforming growth factor (TGF) inhibitors
US7417041B2 · kind B2 · utility
15Cited by
8References
6Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Feb 20, 2004 |
| Grant date | Aug 26, 2008 |
| Priority date | — |
| Expiry date | Aug 26, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D513/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Novel fused heteroaromatic compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)-β signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer and fibrotic diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.